OCT/05/09 VeriChip Corporation Selects Raytheon Microelectronics to Manufacture its Products
"Company will use Raytheon/ELCAN Optical Technologies to manufacture its VeriChip patient identification microchip, its new 8-mm microchip and its glucose-sensing microchip which is currently under development
DELRAY BEACH, FL – October 5, 2009 – VeriChip Corporation ("VeriChip" or the "Company") (NASDAQ: CHIP) today announced that it has selected Raytheon Microelectronics España (operating as “ELCAN Optical Technologies") for the production of the Company's radio frequency identification (RFID) implantable microchips, including its existing VeriChip microchip for patient identification, its new 8 millimeter microchip for use in Medical Components, Inc.'s (Medcomp) vascular access medical devices, and its glucose-sensing RFID microchip currently under development with RECEPTORS, LLC.
In December 2008, VeriChip purchased all intellectual property related to its implantable RFID business line from Digital Angel Corporation and canceled its manufacturing relationship. Now, the Company is properly aligned and prepared to re-establish its manufacturing capabilities and has chosen to do so with ELCAN Optical Technologies. Scott R. Silverman, VeriChip's Chairman and CEO, said, "We are pleased to partner with a company that has the name and reputation that ELCAN brings with it."
About ELCAN Optical Technologies (Raytheon Microelectronics España)
ELCAN Optical Technologies is a fully integrated provider of custom, precision optical and electronic solutions for medical, defense & security and commercial customers. ELCAN Optical Technologies, with manufacturing facilities in Midland Ontario, Richardson Texas and Málaga Spain is part of the Raytheon Network Centric Systems group of companies. The Raytheon Company, with 2008 sales of $23.2 billion, is a technology leader specializing in defense, homeland security and other government markets throughout the world. Raytheon provides state-of-the-art electronics, mission systems integration and other capabilities in the areas of sensing; effects; and command, control, communications and intelligence systems, as well as a broad range of mission support services. With headquarters in Waltham, Mass., Raytheon employs 73,000 people worldwide.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida, has developed the VeriMed™ Health Link System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip and corresponding personal health record, cleared for medical use in October 2004 by the United States Food and Drug Administration.
On September 8, 2009, VeriChip Corporation announced it agreed to acquire Steel Vault Corporation (OTCBB: SVUL) to form PositiveID Corporation. PositiveID will provide identification technologies and tools to protect consumers and businesses. The companies expect the merger to close in the fourth quarter of 2009.
For more information on VeriChip, please call 1-800-970-2447, or e-mail info@verichipcorp.com. Additional information can be found online at www.verichipcorp.com.
Statements about VeriChip’s future expectations, including that the Company is properly aligned and prepared to re-establish its manufacturing capabilities, that the name and reputation that ECLAN brings with it will benefit the Company, the Company’s and RECEPTORS’ ability to successfully develop a glucose-sensing RFID microchip, that the companies expect the merger to close in the fourth quarter of 2009, and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and VeriChip’s actual results could differ materially from expected results. These risks and uncertainties include the Company’s ability to successfully develop and commercialize the glucose-sensing microchip, the market acceptance of the glucose-sensing microchip, the Company’s and RECEPTORS’ ability to develop a glucose-sensing microchip, the validity, scope and enforceability of the Company’s patents and those related to the glucose-sensing microchip, the protection afforded by the Company’s patents and those related to the microchips, the Company’s ability to complete the development phases in certain time frames, government regulations relating to the microchips, the Company’s ability to fund the continued development of the glucose-sensing microchip, the timing and success of submission, acceptance and approval of required regulatory filings; as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on February 12, 2009, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Additional Information and Where to Find It
On September 8, 2009, VeriChip and Steel Vault issued a joint press release announcing the signing of an Agreement and Plan of Reorganization, among VeriChip, Steel Vault and VeriChip Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of VeriChip (the “Acquisition Subsidiary”), pursuant to which the Acquisition Subsidiary will be merged with and into Steel Vault, with Steel Vault surviving and becoming a wholly-owned subsidiary of VeriChip (the “Merger”). Upon the consummation of the Merger, each outstanding share of Steel Vault’s common stock will be converted into 0.5 shares of VeriChip common stock.
In connection with the Merger, VeriChip filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 that will contain a Joint Proxy Statement/Prospectus of VeriChip and Steel Vault. Investors and security holders are urged to read the Registration Statement and the Joint Proxy Statement/Prospectus carefully because they contain important information about VeriChip, Steel Vault and the proposed transaction. The Joint Proxy Statement/Prospectus and other relevant materials (when they become available), and any other documents filed with the SEC, may be obtained free of charge at the SEC’s web site (www.sec.gov). In addition, investors and security holders may obtain a free copy of other documents filed by VeriChip or Steel Vault by directing a written request, as appropriate, to VeriChip at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations, or to Steel Vault at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations.
Investors and security holders are urged to read the Joint Proxy Statement/Prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed transaction.
VeriChip, Steel Vault and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the interests of these directors and executive officers in the proposed transaction will be included in the Joint Proxy Statement/Prospectus referred to above. Additional information regarding the directors and executive officers of VeriChip is also included in VeriChip's Form 10-K, which was filed with the SEC on February 12, 2009.
Additional information regarding the directors and executive officers of Steel Vault is also included in Steel Vault's proxy statement (Form DEF 14A) for the 2009 annual meeting of Steel Vault's stockholders, which was filed with the SEC on February 9, 2009, as amended. These documents are available free of charge at the SEC’s website (www.sec.gov) and by contacting Investor Relations at the addresses above.
Contact:
Steel Vault Corporation
Allison Tomek
561-805-8000
atomek@steelvaultcorp.com "
DELRAY BEACH, FL – October 5, 2009 – VeriChip Corporation ("VeriChip" or the "Company") (NASDAQ: CHIP) today announced that it has selected Raytheon Microelectronics España (operating as “ELCAN Optical Technologies") for the production of the Company's radio frequency identification (RFID) implantable microchips, including its existing VeriChip microchip for patient identification, its new 8 millimeter microchip for use in Medical Components, Inc.'s (Medcomp) vascular access medical devices, and its glucose-sensing RFID microchip currently under development with RECEPTORS, LLC.
In December 2008, VeriChip purchased all intellectual property related to its implantable RFID business line from Digital Angel Corporation and canceled its manufacturing relationship. Now, the Company is properly aligned and prepared to re-establish its manufacturing capabilities and has chosen to do so with ELCAN Optical Technologies. Scott R. Silverman, VeriChip's Chairman and CEO, said, "We are pleased to partner with a company that has the name and reputation that ELCAN brings with it."
About ELCAN Optical Technologies (Raytheon Microelectronics España)
ELCAN Optical Technologies is a fully integrated provider of custom, precision optical and electronic solutions for medical, defense & security and commercial customers. ELCAN Optical Technologies, with manufacturing facilities in Midland Ontario, Richardson Texas and Málaga Spain is part of the Raytheon Network Centric Systems group of companies. The Raytheon Company, with 2008 sales of $23.2 billion, is a technology leader specializing in defense, homeland security and other government markets throughout the world. Raytheon provides state-of-the-art electronics, mission systems integration and other capabilities in the areas of sensing; effects; and command, control, communications and intelligence systems, as well as a broad range of mission support services. With headquarters in Waltham, Mass., Raytheon employs 73,000 people worldwide.
About VeriChip Corporation
VeriChip Corporation, headquartered in Delray Beach, Florida, has developed the VeriMed™ Health Link System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip and corresponding personal health record, cleared for medical use in October 2004 by the United States Food and Drug Administration.
On September 8, 2009, VeriChip Corporation announced it agreed to acquire Steel Vault Corporation (OTCBB: SVUL) to form PositiveID Corporation. PositiveID will provide identification technologies and tools to protect consumers and businesses. The companies expect the merger to close in the fourth quarter of 2009.
For more information on VeriChip, please call 1-800-970-2447, or e-mail info@verichipcorp.com. Additional information can be found online at www.verichipcorp.com.
Statements about VeriChip’s future expectations, including that the Company is properly aligned and prepared to re-establish its manufacturing capabilities, that the name and reputation that ECLAN brings with it will benefit the Company, the Company’s and RECEPTORS’ ability to successfully develop a glucose-sensing RFID microchip, that the companies expect the merger to close in the fourth quarter of 2009, and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and VeriChip’s actual results could differ materially from expected results. These risks and uncertainties include the Company’s ability to successfully develop and commercialize the glucose-sensing microchip, the market acceptance of the glucose-sensing microchip, the Company’s and RECEPTORS’ ability to develop a glucose-sensing microchip, the validity, scope and enforceability of the Company’s patents and those related to the glucose-sensing microchip, the protection afforded by the Company’s patents and those related to the microchips, the Company’s ability to complete the development phases in certain time frames, government regulations relating to the microchips, the Company’s ability to fund the continued development of the glucose-sensing microchip, the timing and success of submission, acceptance and approval of required regulatory filings; as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on February 12, 2009, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Additional Information and Where to Find It
On September 8, 2009, VeriChip and Steel Vault issued a joint press release announcing the signing of an Agreement and Plan of Reorganization, among VeriChip, Steel Vault and VeriChip Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of VeriChip (the “Acquisition Subsidiary”), pursuant to which the Acquisition Subsidiary will be merged with and into Steel Vault, with Steel Vault surviving and becoming a wholly-owned subsidiary of VeriChip (the “Merger”). Upon the consummation of the Merger, each outstanding share of Steel Vault’s common stock will be converted into 0.5 shares of VeriChip common stock.
In connection with the Merger, VeriChip filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 that will contain a Joint Proxy Statement/Prospectus of VeriChip and Steel Vault. Investors and security holders are urged to read the Registration Statement and the Joint Proxy Statement/Prospectus carefully because they contain important information about VeriChip, Steel Vault and the proposed transaction. The Joint Proxy Statement/Prospectus and other relevant materials (when they become available), and any other documents filed with the SEC, may be obtained free of charge at the SEC’s web site (www.sec.gov). In addition, investors and security holders may obtain a free copy of other documents filed by VeriChip or Steel Vault by directing a written request, as appropriate, to VeriChip at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations, or to Steel Vault at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations.
Investors and security holders are urged to read the Joint Proxy Statement/Prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed transaction.
VeriChip, Steel Vault and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the interests of these directors and executive officers in the proposed transaction will be included in the Joint Proxy Statement/Prospectus referred to above. Additional information regarding the directors and executive officers of VeriChip is also included in VeriChip's Form 10-K, which was filed with the SEC on February 12, 2009.
Additional information regarding the directors and executive officers of Steel Vault is also included in Steel Vault's proxy statement (Form DEF 14A) for the 2009 annual meeting of Steel Vault's stockholders, which was filed with the SEC on February 9, 2009, as amended. These documents are available free of charge at the SEC’s website (www.sec.gov) and by contacting Investor Relations at the addresses above.
Contact:
Steel Vault Corporation
Allison Tomek
561-805-8000
atomek@steelvaultcorp.com "
"Destroying the New World Order"
THANK YOU FOR SUPPORTING THE SITE!
Latest Activity
- Top News
- Everything
"Wow! The final progressive steps to the government run matrix. Now just fine tuning it. I…"
"That's a great poem it's a good time for writing being national poetry month in America…"
"All good points guys and perhaps in the future we'll see some new freak show of mRNA vax that…"
"SSRI's are poor substute for counciling soldiers back from war suffering from PTSD! "
Trump FULLY SURRENDERS to Iran giving them HORMUZ FOREVER!!!
"Iranians were controlling that strait from more than 2000 years so, i don't see how can U.S.…"
"About that...FDA is known to be covering all kind of stories for big pharma... including all you…"
"Medicines are made for different types of budgets and different types of diseases, doesn't…"
Stupidity...
So, these days patients don't read the prospect of a medicine before using it?See More
This Isn’t a Theory Anymore — The Thiel/Epstein Power Network Is Being Built Now | Whitney Webb
What if the system people keep warning about isn’t some future plan?What if it’s already here — being built in plain sight through defense contracts, digital...
© 2026 Created by truth.
Powered by
